The downregulation of the expression of anti-apoptotic genes such as Bcl-2 and Bcl-X makes cancer cells more vulnerable to apoptosis and, in cellular models with Bcl-2 overexpression, some analogs deactivate the Fas (CD95)-associated protein with death domain, resulting in programmed cell death [28]. The gene discussed is BCL2; the disease is cancer.